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Abstract  
 
Research aims to improve health outcomes for patients. However, the setting of research priorities is usually 
determined by clinicians, academics and funders, with little involvement by patients or caregivers, using 
processes that lack transparency. A national workshop was convened to generate and prioritize research 
questions in chronic kidney disease (CKD) among diverse stakeholder groups. Patients with CKD (n=23), 
caregivers (n=7), nephrologists/surgeons (n=16), nurses (n=8), and allied health professionals and 
researchers (n=4) generated and voted on intervention questions across four treatment stages: Stage 1-5 
CKD (non-dialysis dependent), peritoneal dialysis, hemodialysis, and kidney transplantation. The five 
highest ranking questions were: 1) How effective are lifestyle programs for preventing deteriorating kidney 
function in early CKD? 2) What strategies will improve family consent for deceased donor kidney donation, 
taking different cultural groups into account? 3) What interventions can improve long-term post-transplant 
outcomes? 4) What are effective interventions for post hemodialysis fatigue? 5) How can we improve and 
individualize drug therapy to control post-transplant side effects?  Priority questions were focused on 
prevention, lifestyle, quality of life, and long-term impact. These prioritized research questions can inform 
patient/consumer organizations, researchers, policy makers, and funding agencies in developing a CKD 
research agenda that is relevant to key stakeholders. 
 
Index words:  Research, clinical research, chronic kidney disease, priority setting, prevention, quality of 
life, patient 
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Research aims to improve treatment and health outcomes for patients but research priorities are usually 
determined by academics, clinicians, and funders, with little input from patients and their caregivers(1-3). 
This doer-end user discordance results in mismatches between topics of importance to patients and their 
families and research actually funded and conducted(3-5). Consequently, clinicians may focus on treatment 
issues to the exclusion of the burdens associated with living with the disease and treatment; and many areas 
of potentially important research are neglected even when a considerable amount of research is publicly 
funded(4, 6, 7).   
 
Recently, the lack of partnership among researchers, clinicians and patients has been recognized in many 
jurisdictions, and major new initiatives have been forged to fill the gap(8, 9). In the US, a major platform of 
recent healthcare reform was the formation of the Patient-Centered Outcomes Research Institute (PCORI), 
with a mission to produce and promote high-integrity research that is “guided by patients, caregivers, and 
the broader healthcare community”(10). In the UK in 2004, the James Lind Alliance was launched to unite 
patients, caregivers, and healthcare providers in prioritizing treatment uncertainties for research(11).  
 
Research prioritization exercises with an explicit process are uncommon in chronic kidney disease (CKD) 
and those that do exist often do not engage key stakeholder groups, including patients and caregivers, in a 
partnership approach(12-17). The notable exception is the research priority setting partnership exercise 
completed in Canada involving patients on or nearing dialysis, physicians and allied health professionals, 
which focused on advanced CKD and dialysis(18). The top 10 priorities addressed patient-provider 
communication, dialysis modalities, itching, access to transplantation, heart health, dietary restrictions, 
depression, and vascular access.   
 
Research priority setting partnerships provide an opportunity for equitable involvement of patients, 
caregivers and healthcare providers, and this can improve the relevance, quality, and implementation of 
research(19).  
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National priority setting workshop 
 
Context 
 
Australia is among the world’s 20 largest economies with a GDP of approximately US$1 trillion. In the 
Australian healthcare system, there are government funded services and services funded by private health 
insurance. Medicare is the Australian Government’s universal health insurance scheme that provides free or 
subsidized treatment to public patients in public hospitals. Costs of dialysis and kidney transplantation are 
covered by Medicare. However, patients may choose to dialyze as a private patient at a private renal unit 
which is funded by private health insurance schemes. 
 
A national priority setting workshop was convened on February 7th, 2014 to generate and prioritize research 
questions in CKD in Australia. The intent of the workshop was to develop a prioritized research agenda 
across the entire spectrum of CKD that is relevant to all key stakeholders – patients, clinicians, policy 
makers, and research funders. 
 
Workshop participants 
 
Participants were eligible if they were patients with CKD (CKD Stage 1-5, 5D, 5T), family caregivers, 
health professionals with experience in CKD (nephrologists, surgeons, nurses or allied health professionals, 
or researchers); English-speaking, aged 18 years and over, and able to provide informed consent. 
Participants were recruited from seven Australian states and territories (New South Wales, Victoria, 
Queensland, Northern Territory, South Australia, Western Australia and the Australian Capital Territory). 
Patients and family caregivers were selected via Kidney Health Australia and recruiting clinicians using 
purposive and snowballing (i.e. participants were asked to nominate other participants) strategies to achieve 
a range of socio-demographic (age, gender, employment status, education, culturally and linguistically 
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diverse populations, location of residence) and clinical characteristics (CKD stage/modality, duration of 
diagnosis) across the country. These criteria were advised to the recruiting organisation and the recruiting 
clinicians. Health professionals and researchers were purposively selected to capture diversity across years 
of clinical experience, age, gender, practice locations, and affiliations with stakeholder organizations 
(Australian Kidney Trials Network (AKTN), Australian Institute of Health and Welfare (AIHW), Australian 
Government Department of Health, National Health and Medical Research Council, Australian and New 
Zealand Society of Nephrology (ANZSN), The Transplantation Society of Australian and New Zealand 
(TSANZ), Australian and New Zealand Dialysis and Transplant Registry (ANZDATA), and Agency for 
Clinical Innovation (ACI), and State Renal Health Clinical Networks). The workshop was convened in hotel 
meeting rooms in central Sydney.  
 
Participants received reimbursement for travel and accommodation. Recruitment continued until the 
maximum of 60 participants were confirmed to attend with at least half being patients/caregivers. The 
workshop capacity was determined by resource availability (approximate budget of AUD $20 000 for direct 
workshop costs excluding personnel salaries), group manageability, and feasibility. All participants were 
asked to complete a declaration of interests and disclosure form. The University of Sydney ethics committee 
approved the study. 
 
Of the 60 confirmed to attend the workshop, 58 (97%) participated in the workshop: patients (n=23), 
caregivers (n=7), nephrologists and surgeon (n=16), nurses (n=8), and allied health professionals and 
researchers (n=4). The number of patients/caregivers who declined participation or those whom we excluded 
to avoid over-recruitment of demographic/clinical characteristics could not be tracked as we used multiple 
recruitment strategies. Eight health professionals declined participation due to prior commitments. The 
participants were aged from 23 to 77 years (mean=49.7 years, SD=12.0); and 34 (58.6%) were men. The 
mean age of patients/caregivers was 52 years (SD=14.7) and 46 years (SD=11.9) for healthcare providers. 
The participant characteristics are provided in Tables 1 and 2. 
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Prioritization process 
 
The process was adapted from the James Lind Alliance Priority Setting Partnership methodology for the 
consensus workshop(20-24) and Viergever’s(25) framework for health research priority setting. The process 
is shown in Figure 1 and the facilitator’s Interview Guide is provided in Table S1.  
 
The facilitators were required to have a background in health (public health, medicine, health economics, 
psychology, or epidemiology), prior experience in moderating focus groups, and were known to the 
investigator team to have the skills required for the task. All facilitators completed a training session which 
covered the workshop objectives, the role and skills of a facilitator, and how to ensure effective dialogue and 
manage difficult behavior. 
 
The one-day workshop had three phrases: 
 
Phase 1: Participants were divided into six facilitated groups of 8 to 10 members. The group composition 
was mixed with patients, caregivers and health professionals; with at least half comprising of 
patients/caregivers. Each group focused on questions for four CKD treatment groups: non-dialysis 
dependent Stage 1-5 CKD (1 group), peritoneal dialysis (1 group), hemodialysis (2 groups) and 
transplantation (2 groups). An additional group was convened for hemodialysis and transplantation based on 
participant preferences submitted prior to the workshop and group facilitation manageability. This also 
reflects the higher proportion of prevalent patients on hemodialysis or who have received a kidney transplant 
in Australia(26). One trained facilitator (SC, AT, GW, KH, AR, SH) and one co-facilitator (SC, JCC, DT, 
CSH, AJ, ML) were assigned to each group. Participants were asked to formulate questions about 
interventions and to try to generate questions following the PICO (population, intervention, comparator, 
outcomes) framework with questions displayed on the board or wall. Each participant was given five sticker 
dots to vote on the five top research questions, then choices were discussed as a group. Additional sticker 
dots were distributed for use in tiebreaking. 
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The top 10 questions for each CKD treatment stage were identified based on a summation of votes. For the 
hemodialysis and transplant groups which had an additional group, the top five from each of the groups were 
combined to form the top 10 for the respective CKD treatment stage, giving four sets of 10 questions, each 
representing a CKD treatment stage. A patient representative from each group reviewed the questions for 
clarity and meaning. 
 
Phase 2: A copy of the top 10 questions for the four CKD stages was provided to each group. The questions 
were categorized by CKD stage and all groups discussed and ranked the four sets of questions. The top five 
ranked questions from each set progressed to the next phase.  
 
Phase 3: The group votes were summed and the aggregate top five questions from each CKD treatment stage 
were distilled into a list of 20 questions. These were presented to all participants in a plenary with 
participants invited to comment or ask questions. Each participant received a printed copy and individually 
ranked the top 20 questions from 1 (most important) to 20 (least important). 
 
A preliminary report of the research priorities workshop (available on request) was sent to all participants 
who were invited to provide feedback and comment within a two-week time frame. 
 
Data analysis 
 
Descriptive statistics were calculated using SPSS (IBM, New York US, version 21). The prioritized list of 
the top 20 research questions for all participants was generated by combining the scores from the top 20 
questions that were individually ranked by participants and calculating the mean and the standard deviation 
(SD) for each question. To investigate if data were skewed, histograms with a normal curve were generated 
for each question. Results revealed that the data were not normally distributed, therefore a median and 
interquartile range were calculated for each question to determine rank. Questions were then stratified by 
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participant group (patients/caregivers vs. health professionals/researchers) and a Mann-Whitney U was 
conducted to test for differences between the groups. 
 
Research priorities 
 
Across all groups, a total of 83 research questions were generated (Table S2). The top 10 questions ranked 
by CKD stage are provided in Box 1.  
 
The individual ranking was completed by 55 (95%) participants. See Table 3 for the top 20 ranked 
questions. The five highest ranking questions across CKD stages ranked according to median scores were:  
 
1) How effective are lifestyle programs (diet, exercise, and smoking cessation) for preventing deteriorating 
kidney function in patients with early CKD?  
2) What strategies will improve family consent for potential deceased donor kidney donation, taking 
different cultural groups into account?  
3) What interventions (drugs, lifestyle) can improve long-term post-transplant outcomes?  
4) What are the effective interventions for post HD fatigue?  
5) How can we improve and individualize drug therapy to provide better control of side effects? 
 
The median and distribution of scores for each question are provided in Supplementary File 3. The priority 
questions focused on prevention, lifestyle, quality of life, and long-term impact.  
 
Table 4 also shows the differences in median scores, inter-quartile range (IQR), and rank between 
patients/caregivers and healthcare providers. The mean, median scores, rank, and distribution of rankings for 
both groups are shown in Supplementary File 4.  The difference in median score and IQR was statistically 
significant for one question: “What interventions are most effective to reduce inter-dialytic weight gain?” 
(15 [IQR 9-18] for patients/caregivers versus 10 [IQR 5-15] for healthcare professionals, P=0.032). 
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Six questions had a difference in rank of five or more between the patients/ caregivers and healthcare 
providers. The questions ranked of higher priority by at least 5 rankings among patient/caregivers were: 1) 
What strategies will improve donor family consent to deceased donation taking different cultural groups into 
account?; and 2) Are electronic and social media an effective modality to deliver health promotion about 
CKD in the general population? The questions ranked of higher priority among healthcare professionals 
were: 1) What are effective interventions for post HD fatigue?; 2) what are the best interventions to improve 
the decision-making process of people faced with HD?; 3) What kinds of exercise programs are safe and 
most effective for PD patients?; and 4) What interventions are most effective to reduce inter-dialytic weight 
gain? 
  
Of the questions ranked in the top 10 by both patients and caregivers, 8 appeared in the overall final top 10 
questions. Of the questions ranked in the lowest 10 by both patients and caregivers, 7 were in the overall 
final 10 lowest ranked questions. The questions ranked in the top seven by patients/caregivers and by 
healthcare professionals were included in the overall top ten research priorities. Both groups ranked the 
research question: “How can technology be used to improve patient self-monitoring in PD?” last which was 
consistent with the rank of the combined group. 
 
A summary report was sent to all participants for feedback and comment; and uploaded on the Kidney 
Health Australia website to disseminate the findings(27). 
 
Discussion 
 
An Australian priority setting partnership involving patients, caregivers, policy makers, clinicians and 
researchers was convened in February 2014 to elicit shared research priorities for CKD. Priorities were 
focused on prevention, lifestyle, quality of life, and long-term impact of disease and treatment. In Stage 1-5 
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CKD (non-dialysis-dependent), the prioritized questions were centered on lifestyle interventions to prevent 
disease progression, education to improve self-management and access to services, health promotion in the 
general community, and referral and support services to improve quality of life. For peritoneal dialysis, the 
questions addressed diet and nutrition, self-monitoring technology, transition, integrated services to improve 
mental health, and educational interventions for staff to reduce complications. The prioritized questions for 
hemodialysis related to managing polypharmacy, shared decision-making, nutritional management, fatigue 
and anxiety, and inter-dialytic weight gain. In transplantation, interventions to improve post-transplant 
outcomes, increase donation rates, individualized therapy to manage side effects, and psychological 
interventions were prioritized. 
 
Overall, there was broad consensus between patients/caregivers and health professionals. This may be partly 
explained by the balanced mix of patients/caregiver and health professionals in each breakout discussion 
group. Also, the nominal group technique allows all participants to contribute ideas (research questions) 
individually, and to discuss the ideas as a group. We sought a process of hearing views equally and all 
groups were moderated by a trained facilitator who encouraged open and collaborative dialogue among all 
participants.  
 
Some questions were noticeable by their absence. There was a lack of discussion about mortality although it 
may have been implicit in some of the generic outcomes identified. Most researchers would regard mortality 
as an important outcome and challenge in chronic kidney disease and many clinical studies are focused on 
mortality – especially in dialysis. The apparent absence of mortality in research priorities has also been 
observed in other areas including cancer, mental health, pulmonary disease where patients/caregivers 
emphasize living with and managing the illness rather than dying from it(5, 28, 29). We speculate that this 
may also reflect a perception that mortality may not be a realistic outcome, particularly in dialysis, given 
that mortality rates remain unacceptably high despite advances in dialysis technologies and pharmacological 
developments (30-32). 
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Comparison with other research priority setting initiatives 
 
Some of the research priorities generated in this workshop reflect priority areas that are consistent with 
findings from a recent systematic review of all research priority setting activities in kidney disease(1). These 
included prevention of progression of CKD, dietary management, access to transplantation, patient 
education and psychosocial impact of CKD. 
 
Recently, the US National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) commissioned 
the Kidney Research National Dialogue to ask practitioners, clinical and basic scientists, and members of 
advocacy and professional groups to identify high-priority research objectives for CKD(16). The research 
objectives covered prevention, prognosis, and treatment and outcomes. Diet and nutrition, and transition 
from pediatric to adult care were the only priorities that were similar to those identified in our study. The US 
Agency for Healthcare Research and Quality (AHRQ) also sought to identify topics for systematic reviews 
of primary research that compared the effectiveness of strategies to prevent, detect, and treat CKD or its 
complications(13). Stakeholder participants were physicians and members of health professional societies, 
health insurance organizations, government, patient advocacy groups – though patients or caregivers were 
not involved. Among the 18 highest ranked priorities for funded comparative effectiveness systematic 
reviews in CKD, approximately one-quarter appear to parallel the research questions prioritized in our 
workshops, and these were: access to healthcare, patient knowledge and education, computer decision 
support for CKD management, and dietary strategies to slow CKD progression. The variation in priorities 
may be largely due to the difference in the priority setting approach used, apriori identification of categories 
and topics by the investigator team, and exclusion of patients and caregivers 
 
Manns et al (2014) conducted a national survey and consensus workshop with patients, caregivers, and 
health professionals to identify research priorities for patients on or nearing dialysis(2). Among the top 10 
research priorities they identified, a number were similar to those identified in our workshop and these 
questions addressed: improving self-management in patients with CKD, shared-decision making, quality of 
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life, increasing access to kidney transplantation, reducing the psychosocial impact of CKD, dietary 
strategies, depression and anxiety, and caregiver support.  
 
Strengths and potential limitations 
 
This national priority setting partnership workshop followed a systematic and transparent process of 
engaging patients, caregivers, clinicians, researchers, and policy makers in generating and prioritizing 
research questions across the spectrum of CKD. This was a large-scale priority setting workshop, which has 
contributed to innovative methodological development through the use of concurrent facilitated discussion 
groups, and a three-phase process with real-time data analysis to distill the number of questions to rank for 
each subsequent phase. We have demonstrated that this approach is effective in allowing participants to 
identify and prioritize research questions.  
 
However, there are several potential limitations. While the purposive sampling strategy captured a range of 
demographic and clinical characteristics, participants from culturally and linguistically diverse 
patients/caregivers were relatively underrepresented (n=8/30 [27%]) and no participants identified as being 
Indigenous Australians (although some participants did advocate for specific Indigenous issues) or resided 
in remote areas. Also, 45% of patients/caregivers were university graduates and acknowledge that this may 
not be reflective of the proportion in the CKD population. The extent to which the priorities address all 
relevant Australian stakeholders may be limited. Differences in research priorities by demographics could 
not be determined as the workshop was designed to develop consensus and not powered to detect differences 
attributed to demographic characteristics. 
 
We recognize that individuals were self-selecting and inevitably may promote a personal or institution 
perspective. However, this was to some extent mitigated by achieving maximum possible variation in 
demographic and clinical characteristics (and recruiting health professionals from different institutions); and 
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having trained facilitators to moderate the discussion to ensure that participants contributed respectfully and 
a wide range of perspectives.  
 	  
The questions formulated did not always fulfill the PICO (population, intervention, control/comparator, 
outcomes) criteria, and so need to be refined further to be answerable with trials or systematic reviews. We 
did not exclude questions that existing research may have already answered, and therefore they may not be 
indicative of uncertainties about CKD treatment. Previous priority setting partnerships following the James 
Lind Alliance approach conducted preliminary surveys and voting exercises to identify and prioritize 
treatment uncertainties, removed questions which had been addressed by existing evidence, and conducted a 
face-to-face workshop to prioritize the remaining questions (20, 24, 33, 34). However, we chose to omit 
these initial steps to ascertain whether patients/caregivers and health professionals could identify research 
questions and priorities together from the onset. We have shown that it is possible to compress the research 
priority setting partnership process, which has implications for cost, resources and feasibility. 
 
The extent to which a one-day priority setting workshop generates decisions that truly reflects the interests 
of patients and their caregivers versus a workshop preceded by prolonged participant engagement and 
process is unknown. Nonetheless, the one-day workshop is a frequently used and accepted approach for 
research priority setting partnerships, and bears some similarities to the consensus development conferences 
outlined in the James Lind Alliance review of priority setting approaches(35). It is also unclear how a 
methodology based on quantitative analysis of the number of times questions are suggested and/or voted for 
compares to a method based on in-depth engagement with patients and their caregivers and qualitative 
analysis to identify their research priorities. However, there is an inherent tension in any process – gathering 
questions from different routes (e.g. group discussions) can yield very similar questions compared to a more 
quantitative survey approach and may give a more nuanced result in terms of the quality of the question. We 
are not aware of a purely qualitative approach that can move engagement towards priorities. 
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Implications for future research priority setting initiatives 
 
The questions generated in our study were explicitly focused on interventions for the treatment and 
management of CKD. Nonetheless, the explicit prioritization mechanism used could be broadly applied in 
other research priority setting exercises. We suggest that prioritization could be conducted for other types of 
research questions which address etiology, diagnosis, and prognosis, or even for exploring the hidden weight 
or burden of living with the disease. Furthermore, there are aspects of living with a serious chronic condition 
which are shared between people regardless of condition, for instance self-managing medicines or broadly-
based health promotion(36). The priorities here could identify issues of importance to a wider group of 
people than those involved in the research. Pediatric kidney disease and non-dialytic care for stage 5 CKD 
were beyond the scope of our study and could be considered for future prioritization initiatives. In 2002, the 
US NIDDK convened a Task Force of Health Professionals who identified five priorities: calcium and 
phosphorus metabolism abnormalities, neurocognitive and development outcomes, predictors of progression 
of structural kidney disease/congenital abnormalities, genetic and molecular risk factors for CKD and their 
effects on outcomes, and the effect of socio-economic factors on outcomes(37). However, it is uncertain 
how well these priorities align with those of patients and caregivers. 
 
Different strategies or approaches to research priority setting may be required for hard to reach communities, 
including Indigenous Australians, who may have different understandings of health, disease, and healthcare 
from the conventional vision of Western medicine(38-41). Relevant, effective and culturally respective 
approaches require a mutually respectful partnership framework, ongoing relationships and engagement, 
capacity building and active involvement of Indigenous staff, an understanding of communities’ past and 
present experience of research, recognition of the diversity of Indigenous populations, and support for 
community ownership(42). 
 
The prioritized research questions generated in our study still need to be mapped against published and 
ongoing research to identify questions which address uncertainties in the evidence. Also, questions may 
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undergo further refinement and distillation according to the PICO criteria and feasibility; after which they 
can be used to inform the development of a CKD research agenda that is important and relevant to key 
stakeholders, particularly patients and caregivers. Forums to formulate research agendas, such as this, will 
drive clinically oriented research to answer questions of immediate relevance and not drive discovery 
research, perhaps a different forum may be more suited to drive discovery research. 
 
Translation of research priorities 
 
A key challenge is translating shared research priorities into the research agendas of funders and researchers. 
Therefore, evaluating the outcomes and impact of priority setting is critical. The findings will be used to 
inform the choice of research projects selected by the national peak consumer organization for kidney 
disease – Kidney Health Australia (KHA). The priorities will also be considered by the Australian Kidney 
Trials Network in planning and design of trials, as well as the Cochrane Renal Group in ensuring that 
systematic reviews of research evidence address topics of concern to patients.    
 
It has been proposed that success is achieved in research priority-setting when there is improved stakeholder 
understanding and confidence in the research prioritization process, a shift in priorities or reallocated 
resources, improvement in decision-making quality in terms of the appropriate use of evidence, stakeholder 
acceptance and satisfaction (or “buy in”), and offers information that is accessible to be used or even 
emulated by others (43). To draw these points out further, success could be “measured” at several stages: 
when research proposals from the research community are aligned with, or reference the prioritization, at the 
stage they are seeking funding; when funding decisions display a resource bias to such aligned proposals; 
and when results from funded proposals are used as an input to subsequent prioritization refinements. 
Ultimately, an increase in the amount of research that reflects the shared priorities of patients/caregivers who 
live with CKD and health professionals would also constitute success. 
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Conclusion 
 
Priority setting partnerships provide an opportunity for participative democratic approaches to research 
question generation(44) and for wide stakeholder engagement to explore and identify research priorities. The 
prioritized research questions can inform patient/consumer organizations, researchers, policy makers, and 
funding agencies in developing a shared CKD research agenda that is relevant to all stakeholders. 
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Table 1. Participant characteristics – patients and caregivers (n=30) 
Characteristic N % 
Patient 23 77 
Caregiver 7 23 
Sex   
Male 16 53 
Female 14 47 
Age (years)   
20 – 29  2 7 
30 – 39 6 20 
40 – 49 6 20 
50 – 59 2 7 
60 – 69  11 37 
70 – 79 3 10 
Employment Status   
Full time 9 31 
Part time 8 28 
Casual 1 3 
Retired 7 24 
Not working 2 7 
Student 2 7 
Marital Status   
Married/defacto 22 73 
Divorced or separated 1 3 
Single (living with parents, never married/defacto) 6 20 
Highest level of education   
Grade 10 4 14 
Grade 12 4 14 
Non-university qualification (Certificate, Diploma) 8 28 
University degree (Bachelor, Masters, Doctoral Degree) 13 45 
Location of residence (state)   
New South Wales 13 43 
Victoria 6 20 
Queensland 4 13 
South Australia 6 20 
Australian Capital Territory 1 3 
Area of residence   
Metropolitan/urban 25 83 
Regional 5 17 
Current mode of renal replacement therapy (of patients)*   
None 6 20 
Hemodialysis 10 33 
Peritoneal dialysis 4 13 
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Kidney transplant 9 30 
Ethnic background   
White 21 70 
Greek 2 7 
Chinese 1 3 
Lebanese 1 3 
Jewish 1 3 
Italian 1 3 
Portuguese 1 3 
Mixed ethnicity 1 3 
*Includes RRT of patients whose caregivers attended the workshop 
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Table 2. Participant characteristics – healthcare professionals (n=28)  
Characteristic n % 
Sex   
Male 18 64 
Female 10 36 
Age (years)   
30 – 39 4 14 
40 – 49 12 43 
50 – 59 10 36 
60 – 69  2 7 
Role   
Nephrologist 14 50 
Surgeon 1 4 
Researcher 1 4 
Dietician 1 4 
Nurse or nurse coordinator 8 29 
Psychologist 1 4 
Social worker 1 4 
Location of practice (state)   
New South Wales 13 46 
Queensland 5 18 
Victoria 3 11 
South Australia 3 11 
Western Australia 2 7 
Australia Capital Territory 1 4 
Northern Territory 1 4 
Years of experience in caring for patients with CKD (years)   
≤ 10 7 25 
11 – 20  7 25 
21 – 30  11 39 
> 30 3 11 
Ethnic background   
Anglo-Saxon 19 68 
Chinese 4 14 
Indian 2 7 
Russian 2 7 
Mixed ethnicity 1 4 
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Table 3. Top 20 research priorities across all stages chronic kidney disease  
 Rank Questiona Allb Patients and 
caregiversc 
Healthcare 
professionalsd 
Mann-Whitney  U 
  Median IQR Median 
(IQR) 
Rank Median 
(IQR) 
Rank U P valuee 
1 How effective are lifestyle 
programs (diet, exercise and 
smoking cessation) for preventing 
deterioration in kidney function in 
patients with early CKD? 
5 2-10 6 (4-10) 
 
4 4 (2- 9) 1 261.5 0.1 
2 What strategies will improve 
donor family consent to deceased 
donation taking different cultural 
groups into account? 
6 3-13 5 (2-11) 1 9(6-13) 6 262.5 0.1 
3 What interventions can improve 
long term post-transplant 
outcomes (drugs, lifestyle)? 
7 2-11 5 (2-11) 1 8 (3-11) 4 314.0 0.5 
4 What are the effective 
interventions for post HD fatigue? 
7 4-14 10 (4-14) 8 6 (4-13) 2 300.5 0.4 
5 What can we do to improve and 
individualize drug therapy in terms 
of better management of side 
effects in kidney transplantation? 
8 4-12 5 (3-11) 3 10 (5-15) 7 245.0 0.01 
6 What strategies help patients 
maintain work while on HD? 
8 4-13 9 (6-14) 7 6 (4-9) 3 243.5 0.06 
7 What psychological interventions 
would improve the psychological 
health for transition between 
kidney stages? 
9 5-16 8 (5-13) 6 11 (5-17) 10 277.5 0.2 
8 How do we improve health 
outcomes in young transplant 
recipients? 
10 5-15 8 (4-14) 5 11 (5-16) 9 305.0 0.4 
9 What are the best interventions to 
improve the decision making 
process of people faced with HD? 
10 6-16 11 (7-16) 13 8 (4-15) 5 269.0 0.1 
10 Does provision of culturally 
appropriate information about 
early CKD modify 
acknowledgement, medication 
adherence, and health service 
uptake in patients with early 
CKD? 
11 6-15 12 (7-16) 15 11 (7-15) 12 324.5 0.6 
11 Do interventions that increase 
knowledge of support services 
and early referral practices 
increase quality of life in patients 
and caregivers? 
11 6-16 10 (5 -14) 9 11 (8-15) 13 309.5 0.5 
12 How can we best provide support 
services to patients, carers, and 
families to improve mental health 
in PD? 
11 7-16 11 (5-16) 10 12 (7-15) 14 341.0 0.9 
13 Does active implementation of 
clinical practice guidelines in 
general practice improve kidney 
health in patients with early CKD? 
12 5-15 11 (5-17) 11 12 (7-15) 14 343.0 0.9 
14 What is the best diet and nutrition 
to improve general health 
outcomes for PD patients? 
12 6-18 12 (8-15) 17 12 (9-16) 16 334.0 0.8 
15 Are electronic and social media 
an effective modality to deliver 
health promotion about CKD in 
the general population? 
12 9-16 11 (6-19) 12 14 (9-17) 19 323.0 0.6 
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16 How can we best deliver staff 
education to reduce patient 
complications in PD? 
13 6-16 12 (8-14) 16 14 (8-18) 18 282.0 0.2 
17 What kinds of exercise programs 
are safe and most effective for PD 
patients? 
13 8-17 15 (10-17) 19 11 (6-15) 11 247.0 0.06 
18 Does implementing a 
personalized care plan increase 
quality of life of HD for patients 
and caregivers? 
13 9-17 12 (6-15) 14 13 (7-16) 17 309.0 0.5 
19 What interventions are most 
effective to reduce inter-dialytic 
weight gain? 
13 8-17 15 (9-18) 18 10 (5-15) 7 230.5 0.03* 
20 How can technology be used to 
improve patient self-monitoring in 
PD? 
18 12-20 17 (12-20) 20 18 (13-20) 20 347.5 0.9 
aTotal n=55, 2 participants did not disclose their identity but their ranking are included in the median calculation; b n=27; c n=26;d 
Interquartile range (25th - 75th ); ep = Asymp.Sig (p) value; *Significant at p<0.05 IQR, interquartile range; SD, standard deviation 
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Box 1. Top 10 ranked* research priorities by CKD stage 
Chronic kidney disease 
1. How effective are lifestyle programs (diet, exercise and smoking cessation) for preventing deterioration in kidney function in 
patients with early CKD? 
2. Does provision of culturally appropriate information about early CKD modify acknowledgement, medication adherence and 
health service uptake in patients with early CKD? 
3. Does active implementation of clinical practice guidelines in general practice improve kidney health in patients with early 
CKD? 
4. Are electronic and social media effective for delivering health promotion about CKD in the general population? 
5. Do interventions that increase knowledge of support services and early referral practices increase quality of life in patients 
and caregivers? 
6. Do interventions that enhance self-management in early CKD patients modify health services use and quality of life? 
7. Do interventions that enhance shared decision making and planning impact on the quality of RRT in patients with early CKD? 
8. Are interventions to enhance education about early CKD detection effective in improving early diagnosis? 
9. Are complementary medicines (e.g. zinc, iron vitamin D) effective in preventing progression of kidney disease in patients with 
early CKD? 
10. Does enhancing  acknowledgement of CKD improve kidney health in patients newly diagnosed with early CKD? 
Peritoneal Dialysis 
1. What is the best diet or nutritional intervention to improve general outcomes of PD patients? 
2. How can technology be used to improve patients’ self-monitoring? 
3. How can we provide better support for patients/ families in transition of care from children to adults? 
4. How we can be best provide support services/tools to be integrated to patients/caregivers/families to improve mental health? 
5. What is the optimum staff/patient ratio in PD clinics to reduce morbidity? 
6. How can we best deliver staff education services to reduce patient complications? 
7. What kinds of exercise program are safe and most effective for PD patients? 
8. Are there interventions or  tools to improve patient cognition and slow decline? 
9. How can peer support be integrated to improve patient mental health? 
10. What is the best way to provide counseling to improve patient self-esteem? 
Hemodialysis 
1. What is the impact of polypharmacy on quality of life; what is the best way to make tablet regimes simpler? 
2. What are the best interventions to improve the decision making process of people faced with HD and to improve their 
satisfaction and reduce complications? 
3. What is the benefit of and what is the best planned nutritional program (plus best ‘easy aids’ to help gauge potassium) for 
better outcomes (improving lean body mass/muscle)? 
4. What are the effective interventions for post HD fatigue? 
5. What strategies reduce anxiety? 
6. What strategies help patients maintain work while on HD? 
7. What are the best characteristics to identify which elderly patients will benefit from HD? 
8. Can a potassium indicator (discrete, measurable) be developed to deal with potassium fluctuation and self-manage better? 
9. What interventions are most effective to reduce interdialytic weight gain in patients with HD? 
10. Does implementing a personalized care plan increase quality of life for patients on HD and caregivers? 
Transplantation 
1. What strategies will improve donor family consent to deceased donation taking different cultural groups into account? 
2. What interventions (medications, lifestyle) can improve long term post-transplant outcomes? 
3. What psychological interventions would improve the psychological health for transition between stages of kidney disease? 
4. How do we improve health outcomes in young transplant recipients? 
5. What can we do to improve/individualize drug therapy in terms of better management of side effects? 
6. Can implementing a pharmacy clinic positively influence compliance and stop transitioning back to dialysis? 
7. What additional psychological and medical support would be beneficial post donation for live donation? 
8. Determining extended criteria for elderly donor recipient pairs (donors over 65 years)? 
9. What counseling services would help children of parents going through the transplant process? 
10. In those with a failing graft would restarting dialysis earlier improve psychological well-being and health? 
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Figure legends 
Figure 1. Flowchart of workshop process 
*n=10 max per group 
**based on removing duplication and top 10 ranked across both lists 
CKD, chronic kidney disease; PD, peritoneal dialysis; HD, hemodialysis; Tx, transplantation; P, population; I, 
intervention; C, comparator; O, outcome; Q, question; mins, minutes 
  
